A new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India has taken an important step forward with positive results from a Phase 1 study.
The recently completed study of the new rabies therapy has shown that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
“We are very encouraged by the results from this trial,” said Donna Ambrosino of MassBiologics.
Subhash Kapre of the Serum Institute of India, agreed saying, “The next step for clinical studies is already in the planning, and we are hopeful that this new therapy will have a major impact on rabies across the globe in the not too distant future.”
While the vaccine is often available, the preferred human rabies immune globulin (HRIG), which is derived from human blood, is expensive material and typically not available in developing countries.
As an alternative to HRIG, equine immune globulin derived from horse serum is used in many parts of the world, but it is also scarce, expensive and can carry significant side effects. Read More…
Discover more from Ebarrelracing.com
Subscribe to get the latest posts sent to your email.
